# Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

> **NCT02215122** · PHASE1 · COMPLETED · sponsor: **Mylan Pharma UK Ltd.** · enrollment: 40 (actual)

## Conditions studied

- Asthma
- COPD

## Interventions

- **DRUG:** MGR001
- **DRUG:** Advair® Diskus®
- **DRUG:** Seretide™ Accuhaler™

## Key facts

- **NCT ID:** NCT02215122
- **Lead sponsor:** Mylan Pharma UK Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215122, "Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02215122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*